FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897781683> ?p ?o ?g. }

• W2897781683 endingPage "e592" @default.
• W2897781683 startingPage "e592" @default.
• W2897781683 abstract "Hypofractionated radiotherapy in 15 or 16 daily fractions is well established as an alternative in early breast cancer after breast-conserving surgery. The evidences for a whole-breast treatment even shorter in 5-10 fractions are still scarce. The objective of the presenting study is to analyse the effects of adjuvant breast cancer radiation using a once-weekly schedule, in 5 fractions. Women 50 years or older, with early breast tumor with negative lymph nodes (pT1-2N0), after breast-conserving surgery with negative margins were eligible to enter in this phase II trial and received whole breast once-weekly hypofractionated radiotherapy to a total dose of 30 Gy, in 5 weekly fractions of 6 Gy. During the treatment and in post treatment follow-up the toxicity was assessed and graduated according the “Common Terminology Criteria for Adverse Events ” (CTCAE), v3.0. The quality of life was evaluated by the EORTC QLQ-30 e QLQ-BR23 questionnaires, that were applied before radiation, immediately after and 1 month after treatment. Breast pictures for aesthetic evaluation were taken in 5 moments and two breast surgeons independently graduated the cosmetics changes. From October 2013 to November 2015, 44 patients were enrolled in the trial and treated according to the protocol of once-weekly radiation. The median age was 70.5 years (51-88 years), and the median follow-up was 22 months (9-33 months). Actinic dermatitis was the most common acute adverse event. At the end of radiation, 30 patients (68,2%) had any grade of radiation dermatitis. Breast pain and hyperpigmentation were the most frequent late events. By the end of the first year of follow-up 53,8% and 51,3% developed breast pain and hyperpigmentation, respectively. Concerning the aesthetic evaluation, for only one of the two observers there was breast appearance alteration over time. For this observer, 63,6% and 13,6% of cases were classified as good or excellent in the evaluations before and after radiotherapy, respectively. After 6 months of treatment completion, 59,1% and 61,4% were aesthetic evaluated as good or excellent by each of the observers. The domain for “social function” was the only one that changed overtime in the quality of life analysis. One month after radiotherapy the median score for “social function” was greater compared to before treatment. The 2-year overall survival and disease-free survival were, respectively 96,8% and 97,7%. There was only one distant recurrence and no local or regional recurrences. Once-weekly hypofractionated radiotherapy is a feasible alternative in early breast cancer management with acceptable acute toxicity and aesthetic alterations and no meaningful quality of life impairment." @default.
• W2897781683 created "2018-10-26" @default.
• W2897781683 creator A5011200560 @default.
• W2897781683 creator A5034873219 @default.
• W2897781683 creator A5079380617 @default.
• W2897781683 creator A5088876748 @default.
• W2897781683 creator A5091256512 @default.
• W2897781683 date "2018-11-01" @default.
• W2897781683 modified "2023-09-25" @default.
• W2897781683 title "Once-Weekly Hypofractionated Radiation Therapy in Breast Cancer: A Phase 2 Trial" @default.
• W2897781683 doi "https://doi.org/10.1016/j.ijrobp.2018.07.1630" @default.
• W2897781683 hasPublicationYear "2018" @default.
• W2897781683 type Work @default.
• W2897781683 sameAs 2897781683 @default.
• W2897781683 citedByCount "0" @default.
• W2897781683 crossrefType "journal-article" @default.
• W2897781683 hasAuthorship W2897781683A5011200560 @default.
• W2897781683 hasAuthorship W2897781683A5034873219 @default.
• W2897781683 hasAuthorship W2897781683A5079380617 @default.
• W2897781683 hasAuthorship W2897781683A5088876748 @default.
• W2897781683 hasAuthorship W2897781683A5091256512 @default.
• W2897781683 hasConcept C121608353 @default.
• W2897781683 hasConcept C126322002 @default.
• W2897781683 hasConcept C141071460 @default.
• W2897781683 hasConcept C197934379 @default.
• W2897781683 hasConcept C2777757722 @default.
• W2897781683 hasConcept C2777793932 @default.
• W2897781683 hasConcept C2781467025 @default.
• W2897781683 hasConcept C509974204 @default.
• W2897781683 hasConcept C530470458 @default.
• W2897781683 hasConcept C71924100 @default.
• W2897781683 hasConceptScore W2897781683C121608353 @default.
• W2897781683 hasConceptScore W2897781683C126322002 @default.
• W2897781683 hasConceptScore W2897781683C141071460 @default.
• W2897781683 hasConceptScore W2897781683C197934379 @default.
• W2897781683 hasConceptScore W2897781683C2777757722 @default.
• W2897781683 hasConceptScore W2897781683C2777793932 @default.
• W2897781683 hasConceptScore W2897781683C2781467025 @default.
• W2897781683 hasConceptScore W2897781683C509974204 @default.
• W2897781683 hasConceptScore W2897781683C530470458 @default.
• W2897781683 hasConceptScore W2897781683C71924100 @default.
• W2897781683 hasIssue "3" @default.
• W2897781683 hasLocation W28977816831 @default.
• W2897781683 hasOpenAccess W2897781683 @default.
• W2897781683 hasPrimaryLocation W28977816831 @default.
• W2897781683 hasRelatedWork W2060905781 @default.
• W2897781683 hasRelatedWork W2126696112 @default.
• W2897781683 hasRelatedWork W2328052505 @default.
• W2897781683 hasRelatedWork W2368745722 @default.
• W2897781683 hasRelatedWork W3028617132 @default.
• W2897781683 hasRelatedWork W3029766897 @default.
• W2897781683 hasRelatedWork W3031152052 @default.
• W2897781683 hasRelatedWork W3032465624 @default.
• W2897781683 hasRelatedWork W4307349053 @default.
• W2897781683 hasRelatedWork W4322772323 @default.
• W2897781683 hasVolume "102" @default.
• W2897781683 isParatext "false" @default.
• W2897781683 isRetracted "false" @default.
• W2897781683 magId "2897781683" @default.
• W2897781683 workType "article" @default.